Skip to content

Altretamine

Published: July 26, 2026Updated: August 24, 2026

Altretamine is an oral antineoplastic agent used primarily in the treatment of refractory ovarian cancer. It functions as a prodrug that is metabolized in the body to form reactive alkylating metabolites, which cross-link DNA strands and prevent cancer cell replication, leading to programmed cell death. This medication is typically reserved for patients who have not responded adequately to other chemotherapy regimens.

Quick summary

Altretamine is an oral chemotherapy agent used for refractory ovarian cancer that works by alkylating DNA to prevent cancer cell division.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 24, 2026Editorial policy

Key facts at a glance

ATC
L01XX03
RxNorm
5296
Generic
Altretamine
Class
atc-l01
Brands
—
Availability
rx
Lactation
unknown
Routes
oral
Forms
capsule
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Dosage and administration

adult (standard)tablet
Usual dose
500mg twice daily
Maximum
consult physician
Frequency
every 12 hours
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
pediatric (standard)tablet
Usual dose
250mg twice daily
Maximum
consult physician
Frequency
every 12 hours
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard
geriatric (standard)tablet
Usual dose
400mg daily
Maximum
consult physician
Frequency
once daily
Instructions
Follow physician instructions
Duration limits
as prescribed
Monitoring
standard

Overdose information

Important overdose information
Toxic dose: Single dose exceeding 10 grams may cause severe toxicity
Chronic overdose: Cumulative doses above 60 mg/kg over multiple cycles may result in severe bone marrow suppression
Immediate actions
Gastric lavage within 1-2 hours of ingestion, activated charcoal administration, supportive care, monitoring of hematologic parameters
Antidote
No specific antidote exists(Supportive care is the primary treatment; no specific antidote proven effective)
Poison Control: 1-800-222-1222

Special Populations

10 groups
✗

pregnancy

first trimester
unsafe
FDA Category
C
Dose Adjustment

avoid if possible

Key Recommendations

avoid use during pregnancy unless benefits outweigh risks - altretamine is an alkylating agent with potential teratogenic effects

Monitor

regular fetal monitoring and ultrasound assessments

Use of this medication in this population requires careful consideration of risks and benefits.

✗

pregnancy

second trimester
unsafe
FDA Category
C
Dose Adjustment

avoid if possible

Key Recommendations

avoid use during pregnancy unless benefits outweigh risks

Monitor

regular fetal monitoring

Use of this medication in this population requires careful consideration of risks and benefits.

✗

pregnancy

third trimester
unsafe
FDA Category
C
Dose Adjustment

avoid if possible

Key Recommendations

avoid use near term - consider delaying treatment until after delivery if possible

Monitor

fetal monitoring and assessment of fetal growth

Use of this medication in this population requires careful consideration of risks and benefits.

✗

lactation

breastfeeding
contraindicated
FDA Category
N
Dose Adjustment

discontinue breastfeeding

Key Recommendations

do not breastfeed during altretamine therapy and for at least 2 weeks after last dose

Monitor

not applicable

Use of this medication in this population requires careful consideration of risks and benefits.

⚠

pediatric_age

children under 18
caution
FDA Category
N
Dose Adjustment

use with caution - limited pediatric data available

Key Recommendations

use only in pediatric oncology settings with experience; dosing based on body surface area

Monitor

close monitoring of hematologic parameters and organ function

Use with caution and monitor for adverse effects.

⚠

geriatric

elderly 65 plus
caution
FDA Category
N
Dose Adjustment

no specific dose adjustment; start at lower end of dosing range

Key Recommendations

monitor renal and hepatic function; assess for comorbidities; increased risk of hematologic toxicity

Monitor

more frequent blood count monitoring and organ function tests

Use with caution and monitor for adverse effects.

⚠

renal_impairment

mild
caution
FDA Category
N
Dose Adjustment

no specific adjustment needed for mild impairment

Key Recommendations

monitor renal function; no initial dose reduction required

Monitor

regular renal function monitoring

Use with caution and monitor for adverse effects.

⚠

renal_impairment

moderate to severe
caution
FDA Category
N
Dose Adjustment

reduce dose based on creatinine clearance

Key Recommendations

reduce initial dose; monitor closely; consider 25-50% dose reduction in severe impairment

Monitor

frequent renal function monitoring and drug level monitoring if available

Use with caution and monitor for adverse effects.

⚠

hepatic_impairment

mild
caution
FDA Category
N
Dose Adjustment

no specific adjustment for mild impairment

Key Recommendations

monitor hepatic function; no initial dose reduction required

Monitor

regular liver function tests

Use with caution and monitor for adverse effects.

⚠

hepatic_impairment

moderate to severe
caution
FDA Category
N
Dose Adjustment

reduce dose; consider 25-50% dose reduction

Key Recommendations

use with extreme caution; monitor hepatic function closely; may require significant dose reduction

Monitor

frequent liver function tests and clinical monitoring

Use with caution and monitor for adverse effects.

Statistics and clinical data

prescribingFDA
2023

FDA approval year

Value:1990

FDA approved for ovarian cancer treatment

drug_classWHO
2023

Drug class

Value:Antineoplastic agent

Chemotherapeutic alkylating agent

usageNCCN
2023

Primary indication

Value:Ovarian cancer

Primary therapeutic use

mechanismFDA
2023

Mechanism of action

Value:Alkylating agent

DNA alkylation causing cross-linking

Primarily used for the treatment of refractory ovarian cancer in patients who have not responded to other chemotherapy agents. May also be investigated for use in other solid tumors in certain circumstances.

Altretamine is a prodrug that undergoes hepatic metabolism to form reactive alkylating intermediates. These metabolites cross-link DNA strands, disrupting DNA replication and transcription, ultimately inducing apoptosis in rapidly dividing cancer cells.

Administered orally in multiple daily doses. Requires regular monitoring of complete blood counts due to risk of bone marrow suppression. May cause neurotoxicity and gastrointestinal side effects. Contraindicated in patients with severe bone marrow suppression or known hypersensitivity. Pregnancy category D - contraindicated during pregnancy due to teratogenic potential.

Contraindications

Conditions and patient states where this medication should be avoided or used with caution.

Do not use (1)

ABSOLUTEhypersensitivity

Known allergy to this medication or its components

Use caution (1)

RELATIVEpregnancy

Consult healthcare provider for benefits vs risks assessment

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy